Wells Fargo & Company Bolt Biotherapeutics, Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.01 - $1.4 $4 - $5	4 Added 1.93%	211 $0
Q4 2023 Feb 09, 2024	BUY	$0.85 - $1.12 $8 - $11	10 Added 5.08%	207 $0
Q3 2023 Nov 13, 2023	BUY	$0.98 - $1.46 $38 - $56	39 Added 24.68%	197 $0
Q2 2023 Aug 15, 2023	BUY	$1.27 - $1.95 $8 - $13	7 Added 4.64%	158 $0
Q1 2023 May 12, 2023	BUY	$1.29 - $1.66 $2 - $3	2 Added 1.34%	151 $0
Q4 2022 Feb 13, 2023	BUY	$1.26 - $1.51 $5 - $6	4 Added 2.76%	149 $0
Q3 2022 Nov 14, 2022	BUY	$1.48 - $2.61 $91 - $161	62 Added 74.7%	145 $0
Q2 2022 Aug 12, 2022	SELL	$1.41 - $2.91 $1,562 - $3,224	-1,108 Reduced 93.03%	83 $0
Q1 2022 May 16, 2022	SELL	$2.74 - $4.82 $22,251 - $39,143	-8,121 Reduced 87.21%	1,191 $3,000
Q4 2021 Feb 14, 2022	BUY	$4.19 - $13.97 $38,786 - $129,320	9,257 Added 16830.91%	9,312 $45,000
Q3 2021 Nov 15, 2021	SELL	$11.15 - $18.6 $1,126 - $1,878	-101 Reduced 64.74%	55 $1,000
Q2 2021 Aug 16, 2021	SELL	$15.4 - $31.46 $58,504 - $119,516	-3,799 Reduced 96.06%	156 $2,000
Q1 2021 May 13, 2021	BUY	$25.86 - $39.93 $102,276 - $157,923	3,955 New	3,955 $130,000

19.1M

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $18.8M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.